» Articles » PMID: 35696066

Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management

Abstract

Conventional vaccines have been widely studied, along with their risk of causing allergic reactions. These generally consist of mild local reactions and only rarely severe anaphylaxis. Although all the current COVID-19 vaccines marketed in Europe have been shown to be safe overall in the general population, early post-marketing evidence has shown that mRNA-based vaccines using novel platforms (i.e., lipid nanoparticles) were associated with an increased risk of severe allergic reactions as compared to conventional vaccines. In this paper we performed an updated literature review on frequency, risk factors, and underlying mechanisms of COVID-19 vaccine-related allergies by searching MEDLINE and Google Scholar databases. We also conducted a qualitative search on VigiBase and EudraVigilance databases to identify reports of "Hypersensitivity" and "Anaphylactic reaction" potentially related to COVID-19 vaccines (Comirnaty, Spikevax, Vaxzevria and COVID-19 Janssen Vaccine), and in EudraVigilance to estimate the reporting rates of "Anaphylactic reaction" and "Anaphylactic shock" after COVID-19 vaccination in the European population. We also summarized the scientific societies' and regulatory agencies' recommendations for prevention and management of COVID-19 vaccine-related allergic reactions, especially in those with a history of allergy.

Citing Articles

Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines.

Lim Q, Lau T, Lai S, Chua G, Zhang K, Lam J J Allergy Clin Immunol Glob. 2025; 4(1):100387.

PMID: 39844915 PMC: 11750530. DOI: 10.1016/j.jacig.2024.100387.


The Ambivalence of Post COVID-19 Vaccination Responses in Humans.

Gopalaswamy R, Aravindhan V, Subbian S Biomolecules. 2024; 14(10).

PMID: 39456253 PMC: 11506738. DOI: 10.3390/biom14101320.


Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.

Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T Vaccines (Basel). 2024; 12(9).

PMID: 39340089 PMC: 11435548. DOI: 10.3390/vaccines12091059.


Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies.

Barta B, Radovits T, Dobos A, Kozma G, Meszaros T, Berenyi P Vaccine X. 2024; 19:100497.

PMID: 38933697 PMC: 11201123. DOI: 10.1016/j.jvacx.2024.100497.


Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database.

Romantowski J, Nazar W, Bojahr K, Popiolek I, Niedoszytko M Life (Basel). 2024; 14(6).

PMID: 38929698 PMC: 11205009. DOI: 10.3390/life14060715.


References
1.
Norton A, Broyles A . Drug allergy in children and adults: Is it the double X chromosome?. Ann Allergy Asthma Immunol. 2018; 122(2):148-155. DOI: 10.1016/j.anai.2018.11.014. View

2.
Broesby-Olsen S, Vestergaard H, Mortz C, Jensen B, Havelund T, Hermann A . Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2017; 73(1):230-238. DOI: 10.1111/all.13237. View

3.
Yang Q, Lai S . Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7(5):655-77. PMC: 4515207. DOI: 10.1002/wnan.1339. View

4.
Zanoni G, Zanotti R, Schena D, Sabbadini C, Opri R, Bonadonna P . Vaccination management in children and adults with mastocytosis. Clin Exp Allergy. 2017; 47(4):593-596. DOI: 10.1111/cea.12882. View

5.
Warren C, Snow T, Lee A, Shah M, Heider A, Blomkalns A . Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open. 2021; 4(9):e2125524. PMC: 8449279. DOI: 10.1001/jamanetworkopen.2021.25524. View